RT Journal Article
SR Electronic
T1 Multicenter analysis of atrioesophageal fistula rates before and after adoption of active esophageal cooling during atrial fibrillation ablation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.21.23286267
DO 10.1101/2023.02.21.23286267
A1 Sanchez, Javier
A1 Woods, Christopher
A1 Zagrodzky, Jason
A1 Nazari, Jose
A1 Singleton, Matthew
A1 Schricker, Amir
A1 Ruppert, Annie
A1 Brumback, Babette
A1 Jenny, Benjamin
A1 Athill, Charles
A1 Joseph, Christopher
A1 Shah, Dipak
A1 Upadhyay, Gaurav
A1 Kulstad, Erik
A1 Cogan, John
A1 Leyton-Mange, Jordan
A1 Cooper, Julie
A1 Tamirisa, Kamala
A1 Omotoye, Samuel
A1 Timilsina, Saroj
A1 Perez-Verdia, Alejandro
A1 Kaplan, Andrew
A1 Patel, Apoor
A1 Ro, Alex
A1 Corsello, Andrew
A1 Kolli, Arun
A1 Greet, Brian
A1 Willms, Danya
A1 Burkland, David
A1 Castillo, Demetrio
A1 Zahwe, Firas
A1 Nayak, Hemal
A1 Daniels, James
A1 MacGregor, John
A1 Sackett, Matthew
A1 Kutayli, Michael
A1 Barakat, Michel
A1 Percell, Robert
A1 Akrivakis, Spyridon
A1 Hao, Steven C.
A1 Liu, Taylor
A1 Panico, Ambrose
A1 Ramireddy, Archana
A1 Lanes, Daniel Benhayon
A1 Sze, Edward
A1 Francisco, Greg
A1 Silva, Jose
A1 McHugh, Julia
A1 Sung, Kai
A1 Feldman, Leon
A1 Serafini, Nicholas
A1 Kawasaki, Raymond
A1 Hongo, Richard
A1 Kuk, Richard
A1 Hayward, Robert
A1 Park, Shirley
A1 Vu, Andrew
A1 Henry, Christopher
A1 Bailey, Shane
A1 Mickelsen, Steven
A1 Taneja, Taresh
A1 Fisher, Westby
A1 Metzl, Mark
YR 2023
UL http://medrxiv.org/content/early/2023/02/23/2023.02.21.23286267.abstract
AB Background Active esophageal cooling reduces the incidence of endoscopically identified severe esophageal lesions during radiofrequency (RF) catheter ablation of the left atrium for the treatment of atrial fibrillation. No atrioesophageal fistula (AEF) has been reported to date with active esophageal cooling, and only one pericardio-esophageal fistula has been reported; however, a formal analysis of the AEF rate with active esophageal cooling has not previously been performed.Methods Atrial fibrillation ablation procedure volumes before and after adoption of active cooling using a dedicated esophageal cooling device (ensoETM, Attune Medical) were determined across 25 hospital systems with the highest total use of esophageal cooling during RF ablation. The number of AEFs occurring in equivalent time frames before and after adoption of cooling were then determined, and AEF rates were compared using generalized estimating equations robust to cluster correlation.Results Throughout the 25 hospital systems, which included a total of 30 separate hospitals, 14,224 patients received active esophageal cooling during RF ablation, with the earliest adoption beginning in March 2019 and the most recent beginning in March 2022. In the time frames prior to adoption of active cooling, a total of 10,962 patients received primarily luminal esophageal temperature (LET) monitoring during their RF ablations. In this pre-adoption cohort a total of 16 AEFs occurred, for an AEF rate of 0.146%, in line with other published estimates of <0.1% to 0.25%. No AEFs were found in the cohort treated after adoption of active esophageal cooling, yielding an AEF rate of 0% (P<0.0001).Conclusion Adoption of active esophageal cooling during RF ablation of the left atrium for the treatment of atrial fibrillation was associated with a significant reduction in AEF rate.Competing Interest StatementChristopher Woods: Consulting for Abbott, Research funding from Biosense Webster, Equity in Inheart Medical, Intellectual property with Attune Medical; Jason Zagrodzky: Consulting for Biosense Webster and Attune Medical; Matthew Singleton: Consulting for Biosense Webster; Babette Brumback: Consulting for Attune Medical; Charles Athill: Consultant for Abbott, Boston Scientific, Biosense Webster, and Acutus, Speaker for Zoll; Christopher Joseph: Internship with Attune Medical; Dipak Shah: Consulting for Abbott, Janssen Pharmaceuticals; Erik Kulstad: Equity and employment in Attune Medical; Gaurav Upadhyay: Consulting for Abbott, Biotronik, Boston Scientific, Medtronic, Philips BioTel, and Zoll Medical; John Cogan: Consulting for Abbott and Biosense Webster; Julie Cooper: Support for data acquisition from Attune Medical; Kamala P. Tamirisa: Speaking for Abbott, Medtronic, Consultant for Sanofi; Apoor Patel: Consulting for Biosense Webster; Brian Greet: Consulting for Medtronic; John F. MacGregor: Research for Boston Scientific; Robert L. Percell: Speaker's bureau for Abbott, Janssen; Steven C. Hao: Consultant for Rampart IC; Ambrose Panico: Consulting for Abbott, Impulse Dynamics; Steven R. Mickelsen: Consulting for Field Medical, Atraverse Medical, Attune Medical; Mark D. Metzl: Consulting for Abbott, Biosense Webster, Attune Medical, Medtronic, Sanofi Aventis, and PhilipsClinical TrialN/AFunding StatementResearch reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R44HL158375 (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Central IRB reviewed (Advarra, Pro00066277) with exempt determination using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(4).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData are available upon reasonable request.